Nuo Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2017
Filed with the SEC on Apr 16, 2018 and accepted by EDGAR at Apr 16, 2018, 16:31 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2017-01-01 to 2017-12-31 | $721.0k | us-gaap:Revenues |
| Cost of revenue | 12 months2017-01-01 to 2017-12-31 | $1.1m | us-gaap:CostOfRevenue |
| Gross profit | 12 months2017-01-01 to 2017-12-31 | −$370.0k | us-gaap:GrossProfit |
| Research and development | 12 months2017-01-01 to 2017-12-31 | $1.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2017-01-01 to 2017-12-31 | −$15.5m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2017-01-01 to 2017-12-31 | −$15.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2017-01-01 to 2017-12-31 | −$1.02 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2017-01-01 to 2017-12-31 | −$1.02 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2017-01-01 to 2017-12-31 | 14,646,112 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2017-01-01 to 2017-12-31 | −$4.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Share repurchases | 12 months2017-01-01 to 2017-12-31 | $471 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2017-12-31 | $693.5k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-12-31 | $1.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-12-31 | $1.4m | us-gaap:Assets |
| Current liabilities | At period end2017-12-31 | $936.8k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-12-31 | $941.2k | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-12-31 | $482.9k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-18-006937. Last ingested by Listed: Nov 14, 2026, 23:44 ET. Listed shows no prices and gives no investment advice.